{"id":"NCT00097786","sponsor":"Novartis Pharmaceuticals","briefTitle":"Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications","officialTitle":"A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-01","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2004-12-01","resultsPosted":"2011-05-24","lastUpdate":"2023-11-08"},"enrollment":9306,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Valsartan 160 mg + nateglinide 60 mg","otherNames":[]},{"type":"DRUG","name":"Valsartan 160 mg + nateglinide placebo","otherNames":[]},{"type":"DRUG","name":"Nateglinide 60 mg + valsartan placebo","otherNames":[]},{"type":"DRUG","name":"Valsartan placebo + nateglinide placebo","otherNames":[]}],"arms":[{"label":"Valsartan 160 mg + nateglinide 60 mg","type":"EXPERIMENTAL"},{"label":"Valsartan 160 mg + nateglinide placebo","type":"EXPERIMENTAL"},{"label":"Nateglinide 60 mg + valsartan placebo","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered \"borderline\" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.","primaryOutcome":{"measure":"Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan","timeFrame":"Mean patient duration of 4.2 years","effectByArm":[{"arm":"Valsartan","deltaMin":33.1,"sd":null},{"arm":"Non-valsartan","deltaMin":36.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":38,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Denmark","Ecuador","Finland","France","Germany","Greece","Guatemala","Hong Kong","Hungary","Italy","Malaysia","Mexico","Netherlands","Norway","Peru","Poland","Russia","Singapore","Slovakia","South Africa","Spain","Sweden","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom","Uruguay"]},"refs":{"pmids":["28087508","26275900","25447626","24861892","24559843","24361242","24322398","20228403","20228402","20184589","20002471","18926145"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1031,"n":2297},"commonTop":["Hypotension","Nasopharyngitis","Dizziness","Arthralgia","Hypoglycaemia"]}}